Analyst firms · Leerink Partners · VRTX

Leerink Partners VRTX price target and rating history

Vertex Pharmaceuticals Incorporated (VRTX) · Health Care

Leerink Partners rates Vertex Pharmaceuticals Incorporated (VRTX) Outperform with a $594 price target, as of its latest action on Sep 21, 2026. It has published 7 rating actions on VRTX since July 2021, including 2 upgrades and 2 downgrades. Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50. Leerink Partners's $594 is 3% above that.

Current rating
Outperform
Price target
$594
Median target, all firms
$577.50
Actions on VRTX
7

Leerink Partners price target on VRTX

$594$382$17020222023202420252026
Leerink Partners price target on VRTX, each point a stated target, July 2021 to September 2026.

Every Leerink Partners rating on VRTX

How other firms rate VRTX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Leerink PartnersOutperform$594Sep 21, 2026
Morgan StanleyOverweight$665Sep 2, 2026
Truist SecuritiesBuy$542May 27, 2026
Maxim GroupBuy$575Mar 18, 2026
JefferiesBuy$580Mar 10, 2026
OppenheimerOutperform$600Mar 10, 2026
BarclaysOverweight$606Jan 28, 2026
RBC Capital MarketsOutperform$546Jan 22, 2026
BernsteinOutperformJan 12, 2026
UBSBuy$535Jan 7, 2026
Wolfe ResearchOutperform$548Jan 6, 2026

Questions about Leerink Partners and VRTX

What is Leerink Partners's price target for VRTX?
Leerink Partners's latest stated price target for Vertex Pharmaceuticals Incorporated (VRTX) is $594, from its action on Sep 21, 2026.
What is Leerink Partners's rating on VRTX?
Leerink Partners rates VRTX Outperform, a bullish rating, as of Sep 21, 2026.
When did Leerink Partners last change its view on VRTX?
On Sep 21, 2026, Leerink Partners starts coverage at Outperform, price target $594.
How does Leerink Partners's VRTX target compare with other analysts?
Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50. Leerink Partners's $594 is 3% above that.

More VRTX rating histories

All Leerink Partners ratingsVRTX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.